Mithra Pharmaceuticals SA
EBR:MITRA.BR
0.216 (EUR) • At close July 23, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) EUR.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 40.155 | 66.997 | 22.668 | 9.03 | 96.52 | 57.876 | 32.042 | 22.468 | 20.435 | 19.038 | 17.677 | 14.752 |
| Cost of Revenue
| 34.164 | 31.563 | 26.15 | 13.33 | 8.264 | 1.571 | 2.595 | 9.029 | 10.195 | 9.988 | 9.054 | 7.438 |
| Gross Profit
| 5.991 | 35.434 | -3.482 | -4.3 | 88.256 | 56.305 | 29.447 | 13.439 | 10.24 | 9.05 | 8.623 | 7.314 |
| Gross Profit Ratio
| 0.149 | 0.529 | -0.154 | -0.476 | 0.914 | 0.973 | 0.919 | 0.598 | 0.501 | 0.475 | 0.488 | 0.496 |
| Reseach & Development Expenses
| 63.17 | 64.041 | 85.243 | 78.458 | 57.073 | 35.713 | 48.185 | 34.299 | 9.585 | 2.614 | 1.378 | 0.546 |
| General & Administrative Expenses
| 22.085 | 14.675 | 12.515 | 15.933 | 14.774 | 8.979 | 8.697 | 8.226 | 10.329 | 6.72 | 4.363 | 2.369 |
| Selling & Marketing Expenses
| 2.271 | 2.1 | 1.871 | 1.434 | 1.539 | 1.977 | 1.734 | 7.567 | 5.009 | 3.028 | 3.534 | 4.218 |
| SG&A
| 12.142 | 4.835 | 3.96 | 7.494 | 10.536 | 10.956 | 10.431 | 15.793 | 15.338 | 9.748 | 7.897 | 6.587 |
| Other Expenses
| 0 | 28.335 | -0.001 | -0.001 | -0.23 | -46.55 | 0 | 0.001 | 0 | 0 | 0.001 | -0.067 |
| Operating Expenses
| 75.312 | 68.876 | 89.204 | 85.953 | 67.839 | 90.336 | 79.253 | 54.021 | 24.54 | 12.092 | 9.181 | 7.066 |
| Operating Income
| -69.321 | -33.442 | -92.686 | -90.253 | 20.417 | 14.188 | -26.162 | -35.976 | -14.268 | -2.929 | -0.557 | 0.248 |
| Operating Income Ratio
| -1.726 | -0.499 | -4.089 | -9.995 | 0.212 | 0.245 | -0.816 | -1.601 | -0.698 | -0.154 | -0.032 | 0.017 |
| Total Other Income Expenses Net
| -92.474 | 19.881 | -33.651 | -22.533 | -53.43 | -51.679 | -25.346 | -4.659 | -0.347 | -0.319 | -0.211 | -0.193 |
| Income Before Tax
| -161.795 | -13.561 | -126.337 | -112.786 | -33.013 | -37.491 | -51.508 | -40.635 | -14.615 | -3.248 | -0.769 | 0.055 |
| Income Before Tax Ratio
| -4.029 | -0.202 | -5.573 | -12.49 | -0.342 | -0.648 | -1.608 | -1.809 | -0.715 | -0.171 | -0.044 | 0.004 |
| Income Tax Expense
| 11.707 | 46.059 | -9.462 | -20.7 | -6.449 | 9.885 | 13.148 | 5.548 | 4.794 | 0.293 | 0.759 | 0.682 |
| Net Income
| -173.502 | -59.62 | -116.875 | -92.086 | -26.564 | -27.606 | -38.36 | -35.087 | -9.821 | -2.955 | -1.528 | -0.627 |
| Net Income Ratio
| -4.321 | -0.89 | -5.156 | -10.198 | -0.275 | -0.477 | -1.197 | -1.562 | -0.481 | -0.155 | -0.086 | -0.043 |
| EPS
| -2.51 | -1.22 | -2.69 | -2.25 | -0.7 | -0.75 | -1.17 | -1.13 | -0.32 | -0.19 | -0.05 | -0.021 |
| EPS Diluted
| -2.51 | -1.22 | -2.69 | -2.25 | -0.7 | -0.75 | -1.17 | -1.13 | -0.32 | -0.19 | -0.05 | -0.021 |
| EBITDA
| -57.107 | -21.502 | -82.26 | -80.38 | 26.194 | 16.895 | -24.12 | -35.068 | -13.593 | -2.19 | -0.035 | 0.743 |
| EBITDA Ratio
| -1.422 | -0.321 | -3.629 | -8.901 | 0.271 | 0.292 | -0.753 | -1.561 | -0.665 | -0.115 | -0.002 | 0.05 |